BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23570983)

  • 1. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
    Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
    J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.
    Zhu S; Wonganan P; Lansakara-P DS; O'Mary HL; Li Y; Cui Z
    Biomaterials; 2013 Mar; 34(9):2327-39. PubMed ID: 23261218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
    Chung WG; Sandoval MA; Sloat BR; Lansakara-P DS; Cui Z
    J Control Release; 2012 Jan; 157(1):132-40. PubMed ID: 21851843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 4-(
    Wang C; Zheng Y; Sand Oval MA; Valdes SA; Chen Z; Lansakara-P DS; Du M; Shi Y; Cui Z
    Oncotarget; 2017 Oct; 8(52):89876-89886. PubMed ID: 29163795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
    De Angel RE; Blando JM; Hogan MG; Sandoval MA; Lansakara-P DS; Dunlap SM; Hursting SD; Cui Z
    Cancer Biol Ther; 2013 Apr; 14(4):357-64. PubMed ID: 23358472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
    Lansakara-P DS; Rodriguez BL; Cui Z
    Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
    Sandoval MA; Sloat BR; Lansakara-P DS; Kumar A; Rodriguez BL; Kiguchi K; Digiovanni J; Cui Z
    J Control Release; 2012 Jan; 157(2):287-96. PubMed ID: 21871505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
    Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; PĂ©rez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
    J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
    Daman Z; Ostad S; Amini M; Gilani K
    Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
    Zhu S; Lansakara-P DS; Li X; Cui Z
    Bioconjug Chem; 2012 May; 23(5):966-80. PubMed ID: 22471294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
    Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
    Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
    Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
    Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles.
    Soni N; Soni N; Pandey H; Maheshwari R; Kesharwani P; Tekade RK
    J Colloid Interface Sci; 2016 Nov; 481():107-16. PubMed ID: 27459173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Just getting into cells is not enough.
    Park K
    J Control Release; 2013 Jul; 169(1-2):162. PubMed ID: 23763953
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
    Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.